Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 4Neuroblastoma 2Neoplasms 2Lymphoma, Large-Cell, Anaplastic 2Lung Neoplasms 2Glioblastoma 2Recurrence 1Lymphoma 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Castration-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1Advanced Cancers 1Advanced Cancer 1Adenocarcinoma 1

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 24Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × Crizotinib × Clear all
NCT01531361 2021-01-22

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

M.D. Anderson Cancer Center

Phase 1 Completed
46 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡